Background The use of antithrombotic agents, including anticoagulants, antiplatelet agents,
and thrombolytics has increased over the last decade and is expected to continue to rise …

Cardiovascular disease (CVD) is the leading cause of death worldwide and is a global
health issue. Traditionally, statistical models are used commonly in the risk prediction and …

▪ Objectives: To assess the effects of invasive procedures, hemostatic and clinical variables,
the timing of beta-blocker therapy, and the doses of recombinant plasminogen activator (rt …

Background—Bolus thrombolytic therapy is a simplified means of administering
thrombolysis that facilitates rapid time to treatment. TNK-tissue plasminogen activator (TNK …

Reperfusion therapies are the mainstay of acute ischemic stroke (AIS) treatments and
overall improve functional outcome. Among the established complications of intravenous …

Thrombolytic therapy improves outcome in patients with myocardial infarction but is
associated with an increased risk of intracranial haemorrhage. For some patients, this risk …

In the Thrombolysis in Myocardial Infarction, Phase II pilot and clinical trial, 908 patients [326
(35.9%) in the pilot study and 582 (64.0%) in the randomized study] were treated with 150 …

Background TNK-tissue plasminogen activator (TNK-TPA) is a genetically engineered
variant of TPA, which in experimental models has a slower plasma clearance and greater …

In patients with acute myocardial infarction, intravenous streptokinase therapy recanalizes
40% to 45% of occluded coronary arteries and reduces mortality by 25%. Recombinant …

As there is even yet a lingering doubt in many minds with regard to some trees, whether they
bear flowers and seed or not, it is the more important to show not only that they do, but for …